Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients
Jonathan Mitchell, Caoilfhionn M Connolly, Teresa Po‐Yu Chiang, Jennifer L. Alejo, William A. Werbel, Dorry L. Segev, Allan B. Massie
Abstract
This cohort study compares the antispike antibody titers of the mRNA-1273 and BNT162b2 vaccines for SARS-CoV-2 in incrementally immunosuppressed patients.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibody responseMedicineCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakMessenger RNAAntibodyImmunologyChemistryInternal medicineGeneInfectious disease (medical specialty)DiseaseOutbreakBiochemistrySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses